Report cover image

MPYS protein inhibitors - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 60 Pages
SKU # DEL18679805

Description

MPYS protein inhibitors - Pipeline Insight, 2024



DelveInsight’s, “MPYS protein inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in MPYS protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
MPYS protein inhibitors Understanding

MPYS protein inhibitors: Overview

Stimulator of interferon genes (STING), also known as transmembrane protein 173 (TMEM173) and MPYS/MITA/ERIS is a protein that in humans is encoded by the STING1 gene. STING plays an important role in innate immunity. STING induces type I interferon production when cells are infected with intracellular pathogens, such as viruses, mycobacteria and intracellular parasites. Type I interferon, mediated by STING, protects infected cells and nearby cells from local infection by binding to the same cell that secretes it (autocrine signaling) and nearby cells (paracrine signaling. It thus plays an important role, for instance, in controlling norovirus infection.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence MPYS protein inhibitors R&D. The therapies under development are focused on novel approaches for MPYS protein inhibitors.
MPYS protein inhibitors Emerging Drugs Chapters

This segment of the MPYS protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

MPYS protein inhibitors Emerging Drugs
  • Veyonda: Noxopharm
Noxopharm's lead drug candidate is called Veyonda® (also known as NOX66) which is being developed as a treatment for cancer and has already advanced to phase 2 clinical trials. It is also being investigated as a treatment for septic shock. As a cancer treatment, Veyonda® is a first-in-class, dual-acting oncotoxic and immuno-modulatory drug candidate designed to enhance the effectiveness and safety of chemotherapy, radiotherapy and immuno-oncology therapy.
  • SB 11736: AstraZeneca
In August 2019, Spring Bank entered into a research agreement with the University of Texas Southwestern Medical School to evaluate its small molecule STING antagonist compounds. SB 11736 is an orally-available STING antagonist.

Further product details are provided in the report……..

MPYS protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different MPYS protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on MPYS protein inhibitors
There are approx. 4+ key companies which are developing the MPYS protein inhibitors. The companies which have their MPYS protein inhibitors drug candidates in the most advanced stage, i.e. Phase II include, Noxopharm.
  • Phases
DelveInsight’s report covers around 4+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
MPYS protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

MPYS protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses MPYS protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging MPYS protein inhibitors drugs.

MPYS protein inhibitors Report Insights
  • MPYS protein inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
MPYS protein inhibitors Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing MPYS protein inhibitors drugs?
  • How many MPYS protein inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of MPYS protein inhibitors?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the MPYS protein inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for MPYS protein inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Noxopharm
  • AstraZeneca
  • F-star Therapeutics
  • Chinook Therapeutics
  • Bayer
  • Nimbus Therapeutics
  • Mavupharma
Key Products
  • Veyonda
  • SB 11736
  • cGAS-STING pathway inhibitor program
  • Research programme: STING antagonists
  • Research programme: small molecule MPYS protein inhibitors
  • MAVU 104

Table of Contents

60 Pages
Introduction
Executive Summary
MPYS protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
MPYS protein inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Veyonda: Noxopharm
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
SB 11736: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
MPYS protein inhibitors Key Companies
MPYS protein inhibitors Key Products
MPYS protein inhibitors- Unmet Needs
MPYS protein inhibitors- Market Drivers and Barriers
MPYS protein inhibitors- Future Perspectives and Conclusion
MPYS protein inhibitors Analyst Views
MPYS protein inhibitors Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us